House committee reviews sweeping health‑care bill to lower costs, boost transparency and curb anti‑competitive contracting

Representative Barrett, the bill's author, told the House Insurance Committee that House Bill 1003 is a comprehensive package intended to lower health‑care costs, fight fraud, expand access, increase transparency and promote competition.

“Lower cost, fight waste, fraud and abuse, enhance transparency, expand access, promote wellness, increase competition,” Barrett said in a high‑level summary of the bill’s pillars. The 43‑page proposal would, among other things, extend certain federal site‑of‑service payment neutrality policies to state Medicaid and commercial plans, require faster good‑faith cost estimates for patients, expand transparency on contracting and claims data, limit anti‑competitive contract terms, streamline provisional credentialing and revise prior‑authorization processes.

Hospital leaders raised concerns about definitions and operational impacts. Tim Kennedy of the Indiana Hospital Association and Rob McClain, CEO of Good Samaritan Hospital in Vincennes, told the committee that undefined terms such as “outpatient setting” and “equivalent outpatient service” could have unintended consequences. McClain said the proposed requirement that outpatient services be reimbursed at the same rate as physician offices could threaten smaller hospitals’ financial stability, noting regulatory and staffing cost differences in outpatient settings. He also warned that the 340B pharmacy provisions could erode savings hospitals use to support uncompensated care and patient assistance funds.

Safety‑net and federally funded clinics urged narrower drafting for 340B language. Witnesses from hemophilia and Ryan White clinics and federally qualified health centers said they already submit detailed HRSA reports and rely on 340B revenue to finance services for low‑income and uninsured patients; several asked the committee to exempt HRSA grantees from any requirement that would eliminate or sharply reduce 340B revenue.

Provider groups sought clarifications on surprise‑billing and good‑faith estimate provisions. The Indiana State Medical Association asked the committee to align state surprise‑billing language with the federal No Surprises Act and to consider the impact of a two‑day good‑faith estimate turnaround (and a later “immediate” requirement) on small practices that may lack electronic tools and staffing to comply quickly.

Employers, manufacturers and business groups supported the bill’s transparency and prior‑authorization reforms as ways to control costs. Representatives of Cummins, the Indiana Manufacturers Association and the Employers Forum praised provisions aimed at correcting site‑of‑service incentives and increasing claims transparency.

Other provisions received broad support from some stakeholders: the director of the Indiana Medicaid Fraud Control Unit said the bill would give investigators additional law‑enforcement tools; the state health secretary praised the bill as advancing the governor’s agenda on affordability; and advocates backed expanded “right to try” language for individualized treatments.

Committee members heard technical feedback across many sections and numerous witnesses requested follow‑up amendments. Representative Barrett said he had already received extensive stakeholder input since listing the bill and expected amendment work before next week’s committee action. The committee did not take a formal vote during the hearing; HB 1003 was presented and heard as a work session and public testimony item.

Ending: The bill would touch multiple parts of the health‑care system and drew supportive statements on goals and cautionary technical feedback about implementation; sponsors signaled continued negotiations on definitions and carveouts (notably for 340B HRSA grantees) before any committee vote.